Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics, GeneMatrix Strike Cancer-Based Pharmacogenomics Collaboration

NEW YORK, Dec. 20 — Variagenics, the Cambridge, Mass.-based pharmacogenomics firm, has launched a pharmacogenomics-based R&D collaboration with the Korean biotechnology company GeneMatrix.

 

The partnership is dedicated to developing new molecular diagnostic products to predict drug response in the treatment of colon and gastric cancer.

 

Under the agreement, GeneMatrix will have access to SNPs and haplotypes that Variagenics has identified. The company will also provide expertise in integrating patient DNA analysis into clinical trials.

 

In return, Variagenics will have access to GeneMatrix data from Asian populations, and plans to make an equity investment in the company. GeneMatrix will also purchase a Variagenics genotyping and haplotyping platform for use in clinical trials.

 

Financial details were not disclosed.

 

The companies anticipate that diagnostic products emerging from this collaboration will be marketable worldwide.

 

GeneMatrix is an early-stage biotech and drug-development company founded in December 2000 by former employees of a major Korean conglomerate, Cheil Jedang. Its current research program focuses on stroke in the Korean population.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.